SNAPSHOTS: Copiktra receives FDA approval for CLL and FL, Relief for tazemetostat developers after FDA lifted partial clinical hold, Conference highlights from 19th WCLC
The United States Food and Drug Administration (USFDA) has granted approval to Verastem’s Copiktra (duvelisib), for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL). The approval was based on positive results from the Phase III DUO trial and Phase II DYNAMO study wherein duvelisib reduced the risk of disease progression by 60% when compared with ofatumumab. The median progression-free survival of 16.4 months with duvelisib and 9....
